Schering Consent Decree Is Weighing Down Operations, CEO Says
This article was originally published in The Rose Sheet
Executive Summary
Schering-Plough's consumer division is among the hardest hit by the firm's ongoing FDA good manufacturing practices consent decree, according to the company
You may also be interested in...
Earnings In Brief
Schering-Plough: Sun care sales soared 60% to $78 mil. in the second quarter, "due to the timing of orders and shipments, coupled with favorable weather conditions," Coppertone marketer reports July 21. Consumer health care sales rose 19% to $317 mil., firm adds. Schering has "good work underway" on new Coppertone and Dr. Scholl's extensions, CEO Fred Hassan says during July 21 earnings call. However, consumer health gains were offset by struggles in Rx pharmaceuticals, spending connected to an FDA consent decree and restructuring costs, company states. Firm reports 7% net sales decline to $2.1 bil. and net loss of $65 mil...
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle